The widespread prevalence and increasing societal cost of chronic pain have led to
the adoption of many treatments. Despite limited short-term evidence, opioids were
recommended, with devastating public health results. In contrast, spinal cord stimulation
(SCS) has been proven to be an effective and cost-effective intervention for chronic
pain in multiple studies using multiple outcome measures.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe toAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Long-term outcomes in use of opioids, nonpharmacologic pain interventions, and total costs of spinal cord stimulators compared with conventional medical therapy for chronic pain.JAMA Neurol. 2023; 80: 18-29
- Impact of spinal cord stimulation on opioid dose reduction: a nationwide analysis.Neurosurgery. 2020; 88: 193-201
- Systemic opioid prescribing patterns and total cost of care in patients initiating spinal cord stimulation therapy: a retrospective analysis.Pain Med. 2021; 22: 784-799
- Association of opioid usage with spinal cord stimulation outcomes.Pain Med. 2018; 19: 699-707
- The health insurer will see you now: How UnitedHealth is keeping more profits, as your doctor.(Accessed December 12, 2022)
Article info
Publication history
Accepted:
January 3,
2023
Received:
January 2,
2023
Footnotes
Conflict of Interest: Salim M. Hayek is currently President of the North American Neuromodulation Society and reported no conflict of interest. Sam Eldabe reports personal: consulting for Medtronic, Mainstay Medical, and Saluda Medical. He also reports institutional research funding from National Institute of Health and Care Research, Boston Scientific, and Medtronic.
Source(s) of financial support: The authors reported no funding sources.
Identification
Copyright
© 2023 International Neuromodulation Society. Published by Elsevier Inc. All rights reserved.
